156 related articles for article (PubMed ID: 32060840)
1. Disparities in glioblastoma survival by case volume: a nationwide observational study.
Raj R; Seppä K; Luostarinen T; Malila N; Seppälä M; Pitkäniemi J; Korja M
J Neurooncol; 2020 Apr; 147(2):361-370. PubMed ID: 32060840
[TBL] [Abstract][Full Text] [Related]
2. Survival trends in glioblastoma and association with treating facility volume.
Aulakh S; DeDeo MR; Free J; Rosenfeld SS; Quinones-Hinojosa A; Paulus A; Manna A; Manochakian R; Chanan-Khan AA; Ailawadhi S
J Clin Neurosci; 2019 Oct; 68():271-274. PubMed ID: 31133366
[TBL] [Abstract][Full Text] [Related]
3. Between-hospital variation in mortality and survival after glioblastoma surgery in the Dutch Quality Registry for Neuro Surgery.
De Witt Hamer PC; Ho VKY; Zwinderman AH; Ackermans L; Ardon H; Boomstra S; Bouwknegt W; van den Brink WA; Dirven CM; van der Gaag NA; van der Veer O; Idema AJS; Kloet A; Koopmans J; Ter Laan M; Verstegen MJT; Wagemakers M; Robe PAJT;
J Neurooncol; 2019 Sep; 144(2):313-323. PubMed ID: 31236819
[TBL] [Abstract][Full Text] [Related]
4. Glioblastoma survival is improving despite increasing incidence rates: a nationwide study between 2000 and 2013 in Finland.
Korja M; Raj R; Seppä K; Luostarinen T; Malila N; Seppälä M; Mäenpää H; Pitkäniemi J
Neuro Oncol; 2019 Feb; 21(3):370-379. PubMed ID: 30312433
[TBL] [Abstract][Full Text] [Related]
5. Association between hospital volume and receipt of treatment and survival in patients with glioblastoma.
Koshy M; Sher DJ; Spiotto M; Husain Z; Engelhard H; Slavin K; Nicholas MK; Weichselbaum RR; Rusthoven C
J Neurooncol; 2017 Dec; 135(3):529-534. PubMed ID: 28836140
[TBL] [Abstract][Full Text] [Related]
6. Clinical practice experience with NovoTTF-100A™ system for glioblastoma: The Patient Registry Dataset (PRiDe).
Mrugala MM; Engelhard HH; Dinh Tran D; Kew Y; Cavaliere R; Villano JL; Annenelie Bota D; Rudnick J; Love Sumrall A; Zhu JJ; Butowski N
Semin Oncol; 2014 Oct; 41 Suppl 6():S4-S13. PubMed ID: 25213869
[TBL] [Abstract][Full Text] [Related]
7. Impact of hospital volume on breast cancer outcome: a population-based study in the Netherlands.
Siesling S; Tjan-Heijnen VC; de Roos M; Snel Y; van Dalen T; Wouters MW; Struikmans H; van der Hoeven JJ; Maduro JH; Visser O
Breast Cancer Res Treat; 2014 Aug; 147(1):177-84. PubMed ID: 25106659
[TBL] [Abstract][Full Text] [Related]
8. Re-irradiation of recurrent glioblastoma as part of a sequential multimodality treatment concept.
Bräutigam E; Lampl C; Track C; Nieder C; Pichler J; Hammer J; Geinitz H
Clin Transl Oncol; 2019 May; 21(5):582-587. PubMed ID: 30284233
[TBL] [Abstract][Full Text] [Related]
9. Improved survival of glioblastoma patients treated at academic and high-volume facilities: a hospital-based study from the National Cancer Database.
Zhu P; Du XL; Zhu JJ; Esquenazi Y
J Neurosurg; 2019 Feb; 132(2):491-502. PubMed ID: 30771780
[TBL] [Abstract][Full Text] [Related]
10. Valproic acid, compared to other antiepileptic drugs, is associated with improved overall and progression-free survival in glioblastoma but worse outcome in grade II/III gliomas treated with temozolomide.
Redjal N; Reinshagen C; Le A; Walcott BP; McDonnell E; Dietrich J; Nahed BV
J Neurooncol; 2016 May; 127(3):505-14. PubMed ID: 26830093
[TBL] [Abstract][Full Text] [Related]
11. Re-irradiation after gross total resection of recurrent glioblastoma : Spatial pattern of recurrence and a review of the literature as a basis for target volume definition.
Straube C; Elpula G; Gempt J; Gerhardt J; Bette S; Zimmer C; Schmidt-Graf F; Meyer B; Combs SE
Strahlenther Onkol; 2017 Nov; 193(11):897-909. PubMed ID: 28616821
[TBL] [Abstract][Full Text] [Related]
12. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma.
Stupp R; Hegi ME; Neyns B; Goldbrunner R; Schlegel U; Clement PM; Grabenbauer GG; Ochsenbein AF; Simon M; Dietrich PY; Pietsch T; Hicking C; Tonn JC; Diserens AC; Pica A; Hermisson M; Krueger S; Picard M; Weller M
J Clin Oncol; 2010 Jun; 28(16):2712-8. PubMed ID: 20439646
[TBL] [Abstract][Full Text] [Related]
13. Hypofractionated Re-irradiation after Maximal Surgical Resection for Recurrent Glioblastoma: Therapeutic Adequacy and Its Prognosticators of Survival.
Lee J; Ahn SS; Chang JH; Suh CO
Yonsei Med J; 2018 Mar; 59(2):194-201. PubMed ID: 29436186
[TBL] [Abstract][Full Text] [Related]
14. Long-term survival of patients suffering from glioblastoma multiforme treated with tumor-treating fields.
Rulseh AM; Keller J; Klener J; Sroubek J; Dbalý V; Syrůček M; Tovaryš F; Vymazal J
World J Surg Oncol; 2012 Oct; 10():220. PubMed ID: 23095807
[TBL] [Abstract][Full Text] [Related]
15. Elderly Patients Strongly Benefit from Centralization of Pancreatic Cancer Surgery: A Population-Based Study.
van der Geest LG; Besselink MG; Busch OR; de Hingh IH; van Eijck CH; Dejong CH; Lemmens VE
Ann Surg Oncol; 2016 Jun; 23(6):2002-9. PubMed ID: 26795767
[TBL] [Abstract][Full Text] [Related]
16. Response patterns of recurrent glioblastomas treated with tumor-treating fields.
Vymazal J; Wong ET
Semin Oncol; 2014 Oct; 41 Suppl 6():S14-24. PubMed ID: 25213870
[TBL] [Abstract][Full Text] [Related]
17. No Difference in Overall Survival Between Hospital Volumes for Patients With Colorectal Cancer in The Netherlands.
Bos AC; van Erning FN; Elferink MA; Rutten HJ; van Oijen MG; de Wilt JH; Lemmens VE
Dis Colon Rectum; 2016 Oct; 59(10):943-52. PubMed ID: 27602925
[TBL] [Abstract][Full Text] [Related]
18. Retroperitoneal sarcoma: a 10-year follow-up analysis using hospital-based cancer registry data in Japan.
Nitta S; Kandori S; Takahashi R; Suzuki S; Hamada K; Tanuma K; Shiga M; Kojo K; Sakka S; Nagumo Y; Hoshi A; Mathis BJ; Negoro H; Okuyama A; Higashi T; Nishiyama H
Jpn J Clin Oncol; 2024 Jun; 54(6):716-721. PubMed ID: 38411262
[TBL] [Abstract][Full Text] [Related]
19. No difference between lowest and highest volume hospitals in outcome after colorectal cancer surgery in the southern Netherlands.
van Erning FN; van Steenbergen LN; van den Broek WT; Rutten HJ; Lemmens VE
Eur J Surg Oncol; 2013 Nov; 39(11):1199-206. PubMed ID: 24044806
[TBL] [Abstract][Full Text] [Related]
20. Observed-to-expected ratio for adherence to treatment guidelines as a quality of care indicator for ovarian cancer.
Galvan-Turner VB; Chang J; Ziogas A; Bristow RE
Gynecol Oncol; 2015 Dec; 139(3):495-9. PubMed ID: 26387962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
